Research programme: thyroid hormone receptor beta agonists - Viking Therapeutics

Drug Profile

Research programme: thyroid hormone receptor beta agonists - Viking Therapeutics

Alternative Names: MB-10866; TR-beta agonists - Viking; VK 0214

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Metabasis Therapeutics
  • Developer Kennedy Krieger Institute; Viking Therapeutics
  • Class Small molecules
  • Mechanism of Action Thyroid hormone receptor beta agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Adrenoleucodystrophy
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Adrenoleucodystrophy; Dyslipidaemias; Non-alcoholic steatohepatitis
  • No development reported Hyperlipidaemia

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Hyperlipidaemia in USA (PO)
  • 23 Oct 2017 Pharmacodynamics and pharmacokinetic data from a preclinical trial in Adrenoleucodystrophy released by Viking Therapeutics
  • 04 Oct 2017 Positive top-line pharmacodynamics data from a preclinical study in Adrenoleucodystrophy released by Viking Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top